Mereo BioPharma faces class action lawsuit for misleading statements.

lunes, 9 de febrero de 2026, 3:32 am ET1 min de lectura
MREO--

Mereo BioPharma Group plc is being sued for alleged violations of securities laws. The company made false and misleading statements about its Phase 3 ORBIT and COSMIC programs, which failed to achieve their endpoints. Shareholders who purchased MREO shares during the class period are encouraged to contact the firm for possible lead plaintiff appointments. The deadline to file a claim is April 6, 2026.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios